Soluble forms of RAGE in internal medicine

Internal and Emergency Medicine

Volumn 4, Issue 5, 2009, Pages 389-401

  Vazzana, Natale ^a   Santilli, Francesca ^a   Cuccurullo, Chiara ^a   Davì, Giovanni ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Atherothrombosis; Biomarkers; Diabetes mellitus; Endogenous secretory RAGE; Inflammation; Oxidative stress; Soluble RAGE

Indexed keywords

ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; BIOLOGICAL MARKER; IMMUNOGLOBULIN RECEPTOR;

HUMAN; INTERNAL MEDICINE; METABOLISM; OXIDATIVE STRESS; REVIEW;

BIOLOGICAL MARKERS; HUMANS; INTERNAL MEDICINE; OXIDATIVE STRESS; RECEPTORS, IMMUNOLOGIC;

EID: 71449100255     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-009-0300-1     Document Type: Review

References (71)

1. Goldin A, Beckman JA, Schmidt AM, Creager MA (2006) Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114: 597-605.
2. Schmidt AM, Yan SD, Yan SF, Stern DM (2000) The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 1498: 99-111.
3. Schmidt AM, Yan SD, Yan SF, Stern DM (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108: 949-955.
4. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, Kislinger T, Stern DM, Schmidt AM, De Caterina R (2002) Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105: 816-822.
5. Santilli F, Vazzana N, Bucciarelli LG, Davì G (2009) Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem 16: 940-952.
6. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger T, Lee DC, Kashyap Y, Stern DM, Schmidt AM (2002) RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106: 2827-2835.
7. Bucciarelli LG, Kaneko M, Ananthakrishnan R, Harja E, Lee LK, Hwang YC, Lerner S, Bakr S, Li Q, Lu Y, Song F, Qu W, Gomez T, Zou YS, Yan SF, Schmidt AM, Ramasamy R (2006) Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation 113: 1226-1234.
8. Raucci A, Cugusi S, Antonelli A, Barabino SM, Monti L, Bierhaus A, Reiss K, Saftig P, Bianchi ME (2008) A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase A Disintegrin And Metalloprotease 10 (ADAM10). FASEB J 22: 3716-3727.
9. Zhang L, Bukulin M, Kojro E, Roth A, Metz VV, Fahrenholz F, Nawroth PP, Bierhaus A, Postina R (2008) Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem 283: 35507-35516.
10. Parkin E, Harris B (2009) A disintegrin and metalloproteinase (ADAM)-mediated ectodomain shedding of ADAM10. J Neurochem 108: 1464-1479.
11. Galichet A, Weibel M, Heizmann CW (2008) Calcium-regulated intramembrane proteolysis of the RAGE receptor. Biochem Biophys Res Commun 370: 1-5.
12. Hudson BI, Carter AM, Harja E, Kalea AZ, Arriero M, Yang H, Grant PJ, Schmidt AM (2008) Identification, classification, and expression of RAGE gene splice variants. FASEB J 22: 1572-1580.
13. Forbes JM, Thorpe SR, Thallas-Bonke V, Pete J, Thomas MC, Deemer ER, Bassal S, El-Osta A, Long DM, Panagiotopoulos S, Jerums G, Osicka TM, Cooper ME (2005) Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 16: 2363-2372.
14. Yamamoto Y, Miura J, Sakurai S, Watanabe T, Yonekura H, Tamei H, Matsuki H, Obata K, Uchigata Y, Iwamoto Y, Koyama H, Yamamoto H (2007) Assaying soluble forms of receptor for advanced glycation end products. Arterioscler Thromb Vasc Biol 27: e33.
15. Ramasamy R, Yan SF, Herold K, Clynes R, Schmidt AM (2008) Receptor for advanced glycation end products: fundamental roles in the inflammatory response: winding the way to the pathogenesis of endothelial dysfunction and atherosclerosis. Ann N Y Acad Sci 1126: 7-13.
16. Falcone C, Emanuele E, D'Angelo A, Buzzi MP, Belvito C, Cuccia M, Geroldi D (2005) Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25: 1032-1037.
17. Lindsey JB, de Lemos JA, Cipollone F, Ayers CR, Rohatgi A, Morrow DA, Khera A and McGuire DK (2009) Association between circulating soluble receptor for advanced glycation end products (sRAGE) and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care 32: 1218-1220.
18. Catalano M, Cortelazzo A, Santi R, Contino L, Demicheli M, Yilmaz Y, Zorzetto M, Campo I, Lanati N, Emanuele E (2008) The Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma2 gene is associated with plasma levels of soluble RAGE (Receptor for Advanced Glycation Endproducts) and the presence of peripheral arterial disease. Clin Biochem 41: 981-985.
19. Lu L, Jin Pu L, Chen QJ, Wang L, Peng W, Yan X, Zhang Q, Yan Zhang R, Gong PH, Qiu JP, Shen WF (2008) Increased glycated albumin and decreased esRAGE concentrations are associated with in-stent restenosis in Chinese diabetic patients. Clin Chim Acta 396: 33-37.
20. Montaner J, Perea-Gainza M, Delgado P, Ribo M, Chacon P, Rosell A, Quintana M, Palacios ME, Molina CA, Alvarez-Sabin J (2008) Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke 39: 2280-2287.
21. Emanuele E, D'Angelo A, Tomaino C, Binetti G, Ghidoni R, Politi P, Bernardi L, Maletta R, Bruni AC, Geroldi D (2005) Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 62: 1734-1736.
22. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T, Yamasaki Y (2008) Endogenous secretory RAGE but not soluble RAGE is associated with carotid atherosclerosis in type 1 diabetes patients. Diab Vasc Dis Res 5: 190-197.
23. Katakami N, Matsuhisa M, Kaneto H, Matsuoka TA, Sakamoto K, Yasuda T, Umayahara Y, Kosugi K and Yamasaki Y (2008) Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. Atherosclerosis 204: 288-292.
24. Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, Emoto M, Tamei H, Matsuki H, Sakurai S, Yamamoto Y, Yonekura H, Watanabe T, Yamamoto H, Nishizawa Y (2005) Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 25: 2587-2593.
25. Katakami N, Matsuhisa M, Kaneto H, Yamasaki Y (2007) Serum endogenous secretory RAGE levels are inversely associated with carotid IMT in type 2 diabetic patients. Atherosclerosis 190: 22-23.
26. Hudson BI, Harja E, Moser B, Schmidt AM (2005) Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein? Arterioscler Thromb Vasc Biol 25: 879-882.
27. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359: 1577-1589.
28. Dluhy RG, McMahon GT (2008) Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 358: 2630-2633.
29. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358: 2545-2559.
30. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560-2572.
31. Basta G, Sironi AM, Lazzerini G, Del Turco S, Buzzigoli E, Casolaro A, Natali A, Ferrannini E, Gastaldelli A (2006) Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 91: 4628-4634.
32. Devangelio E, Santilli F, Formoso G, Ferroni P, Bucciarelli L, Michetti N, Clissa C, Ciabattoni G, Consoli A, Davì G (2007) Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med 43: 511-518.
33. Davì G, Patrono C (2007) Platelet activation and atherothrombosis. N Engl J Med 357: 2482-2494.
34. Geroldi D, Falcone C, Emanuele E, D'Angelo A, Calcagnino M, Buzzi MP, Scioli GA, Fogari R (2005) Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 23: 1725-1729.
35. Norata GD, Garlaschelli K, Grigore L, Tibolla G, Raselli S, Redaelli L, Buccianti G, Catapano AL (2009) Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutr Metab Cardiovasc Dis 19: 129-134.
36. Yilmaz Y, Ulukaya E, Gul OO, Arabul M, Gul CB, Atug O, Oral AY, Aker S and Dolar E (2009) Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clin Biochem 42(9): 802-807.
37. Santilli F, Bucciarelli L, Noto D, Cefalu AB, Davi V, Ferrante E, Pettinella C, Averna MR, Ciabattoni G, Davì G (2007) Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic Biol Med 43: 1255-1262.
38. Hudson BI, Wendt T, Bucciarelli LG, Rong LL, Naka Y, Yan SF, Schmidt AM (2005) Diabetic vascular disease: it's all the RAGE. Antioxid Redox Signal 7: 1588-1600.
39. Grossin N, Wautier MP, Meas T, Guillausseau PJ, Massin P, Wautier JL (2008) Severity of diabetic microvascular complications is associated with a low soluble RAGE level. Diabetes Metab 34: 392-395.
40. Koyama H, Yamamoto H, Nishizawa Y (2007) RAGE and soluble RAGE: potential therapeutic targets for cardiovascular diseases. Mol Med 13: 625-635.
41. Humpert PM, Papadopoulos G, Schaefer K, Djuric Z, Konrade I, Morcos M, Nawroth PP, Bierhaus A (2007) sRAGE and esRAGE are not associated with peripheral or autonomic neuropathy in type 2 diabetes. Horm Metab Res 39: 899-902.
42. Semba RD, Ferrucci L, Fink JC, Sun K, Beck J, Dalal M, Guralnik JM, Fried LP (2009) Advanced glycation end products and their circulating receptors and level of kidney function in older community-dwelling women. Am J Kidney Dis 53: 51-58.
43. Nin JW, Ferreira I, Schalkwijk CG, Prins MH, Chaturvedi N, Fuller JH, Stehouwer CD (2009) Levels of soluble receptor for AGE are cross-sectionally associated with cardiovascular disease in type 1 diabetes, and this association is partially mediated by endothelial and renal dysfunction and by low-grade inflammation: the EURODIAB Prospective Complications Study. Diabetologia 52: 705-714.
44. Koyama H, Shoji T, Fukumoto S, Shinohara K, Emoto M, Mori K, Tahara H, Ishimura E, Kakiya R, Tabata T, Yamamoto H, Nishizawa Y (2007) Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler Thromb Vasc Biol 27: 147-153.
45. Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y, Lalla E, Chitnis S, Monteiro J, Stickland MH, Bucciarelli LG, Moser B, Moxley G, Itescu S, Grant PJ, Gregersen PK, Stern DM, Schmidt AM (2002) RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 3: 123-135.
46. Pullerits R, Bokarewa M, Dahlberg L, Tarkowski A (2005) Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 7: R817-R824.
47. Chen YS, Yan W, Geczy CL, Brown MA, Thomas R (2009) Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther 11: R39.
48. Leach ST, Yang Z, Messina I, Song C, Geczy CL, Cunningham AM, Day AS (2007) Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol 42: 1321-1331.
49. Kim W, Hudson BI, Moser B, Guo J, Rong LL, Lu Y, Qu W, Lalla E, Lerner S, Chen Y, Yan SS, D'Agati V, Naka Y, Ramasamy R, Herold K, Yan SF, Schmidt AM (2005) Receptor for advanced glycation end products and its ligands: a journey from the complications of diabetes to its pathogenesis. Ann N Y Acad Sci 1043: 553-561.
50. Chen X, Walker DG, Schmidt AM, Arancio O, Lue LF, Yan SD (2007) RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med 7: 735-742.
51. Ghidoni R, Benussi L, Glionna M, Franzoni M, Geroldi D, Emanuele E, Binetti G (2008) Decreased plasma levels of soluble receptor for advanced glycation end products in mild cognitive impairment. J Neural Transm 115: 1047-1050.
52. Sternberg Z, Weinstock-Guttman B, Hojnacki D, Zamboni P, Zivadinov R, Chadha K, Lieberman A, Kazim L, Drake A, Rocco P, Grazioli E, Munschauer F (2008) Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity. Mult Scler 14: 759-763.
53. Ilzecka J (2008) Serum-soluble receptor for advanced glycation end product levels in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 120: 119-122.
54. Logsdon CD, Fuentes MK, Huang EH, Arumugam T (2007) RAGE and RAGE ligands in cancer. Curr Mol Med 7: 777-789.
55. Abe R, Yamagishi S (2008) AGE-RAGE system and carcinogenesis. Curr Pharm Des 14: 940-945.
56. Tesarova P, Kalousova M, Jachymova M, Mestek O, Petruzelka L, Zima T (2007) Receptor for advanced glycation end products (RAGE)-soluble form (sRAGE) and gene polymorphisms in patients with breast cancer. Cancer Invest 25: 720-725.
57. Jang Y, Kim JY, Kang SM, Kim JS, Chae JS, Kim OY, Koh SJ, Lee HC, Ahn CW, Song YD, Lee JH (2007) Association of the Gly82Ser polymorphism in the receptor for advanced glycation end products (RAGE) gene with circulating levels of soluble RAGE and inflammatory markers in nondiabetic and nonobese Koreans. Metabolism 56: 199-205.
58. Gu H, Yang L, Sun Q, Zhou B, Tang N, Cong R, Zeng Y, Wang B (2008) Gly82Ser polymorphism of the receptor for advanced glycation end products is associated with an increased risk of gastric cancer in a Chinese population. Clin Cancer Res 14: 3627-3632.
59. Mukherjee TK, Mukhopadhyay S, Hoidal JR (2008) Implication of receptor for advanced glycation end product (RAGE) in pulmonary health and pathophysiology. Respir Physiol Neurobiol 162: 210-215.
60. van Zoelen MA, Schouten M, de Vos AF, Florquin S, Meijers JC, Nawroth PP, Bierhaus A, van der Poll T (2009) The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia. J Immunol 182: 4349-4356.
61. Uchida T, Shirasawa M, Ware LB, Kojima K, Hata Y, Makita K, Mednick G, Matthay ZA, Matthay MA (2006) Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am J Respir Crit Care Med 173: 1008-1015.
62. Bopp C, Bierhaus A, Hofer S, Bouchon A, Nawroth PP, Martin E, Weigand MA (2008) Bench-to-bedside review: the inflammation-perpetuating pattern-recognition receptor RAGE as a therapeutic target in sepsis. Crit Care 12: 201.
63. Hudson BI, Schmidt AM (2004) RAGE: a novel target for drug intervention in diabetic vascular disease. Pharm Res 21: 1079-1086.
64. Kalousova M, Germanova A, Jachymova M, Mestek O, Tesar V, Zima T (2008) A419C (E111A) polymorphism of the glyoxalase I gene and vascular complications in chronic hemodialysis patients. Ann N Y Acad Sci 1126: 268-271.
65. Sullivan CM, Futers TS, Barrett JH, Hudson BI, Freeman MS, Grant PJ (2005) RAGE polymorphisms and the heritability of insulin resistance: the Leeds family study. Diab Vasc Dis Res 2: 42-44.
66. Zee RY, Romero JR, Gould JL, Ricupero DA, Ridker PM (2006) Polymorphisms in the advanced glycosylation end product-specific receptor gene and risk of incident myocardial infarction or ischemic stroke. Stroke 37: 1686-1690.
67. Hudson BI, Stickland MH, Futers TS, Grant PJ (2001) Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 50: 1505-1511.
68. Falcone C, Geroldi D, Buzzi MP, Emanuele E, Yilmaz Y, Fontana JM, Vignali L, Boiocchi C, Sbarsi I, Cuccia M (2008) The -374T/A RAGE polymorphism protects against future cardiac events in nondiabetic patients with coronary artery disease. Arch Med Res 39: 320-325.
69. Pettersson-Fernholm K, Forsblom C, Hudson BI, Perola M, Grant PJ, Groop PH, Finn-Diane Study Group (2003) The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes 52: 891-894.
70. Kim OY, Jo SH, Jang Y, Chae JS, Kim JY, Hyun YJ, Lee JH (2009) G allele at RAGE SNP82 is associated with proinflammatory markers in obese subjects. Nutr Res 29: 106-113.
71. Prevost G, Fajardy I, Besmond C, Balkau B, Tichet J, Fontaine P, Danze PM, Marre M, Genediab and D. E. S. I. R studies (2005) Polymorphisms of the receptor of advanced glycation endproducts (RAGE) and the development of nephropathy in type 1 diabetic patients. Diabetes Metab 31: 35-39.